SCHEMBL22909484

SCHEMBL22909484

CN(C)S(=O)(=O)c1c(F)c(F)c(F)c(F)c1Nc1ccc(C#N)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
SIRT2 Q8IXJ6 4/20 0.39
KCNJ6 P48051 1/20 0.36
KCNJ5 P48544 1/20 0.36
KCNJ3 P48549 1/20 0.36
KDM4E B2RXH2 2/20 0.36
KMT2A Q03164 2/20 0.36
TSHR P16473 1/20 0.36
LMNA P02545 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
POLB P06746 1/20 0.36
RORC P51449 2/20 0.35
HTT P42858 2/20 0.35
SYK P43405 1/20 0.35
HPGD P15428 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MEN1 O00255 1/20 0.35
KDM1A O60341 2/20 0.35
TBXA2R P21731 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29671275 0.82 CA2 (0.48) CA1CA2KDM4ETSHRPOLB
SCHEMBL22909474 0.81 SIRT2 (0.40) SIRT2KDM4EKMT2AMEN1
SCHEMBL22909454 0.76 LMNA (0.41) KMT2ALMNASMN1; SMN2ALDH1A1
SCHEMBL29729069 0.73 L3MBTL1 (0.46) KMT2ASMN1; SMN2ALDH1A1MEN1
SCHEMBL22909462 0.73 L3MBTL1 (0.46) KMT2ASMN1; SMN2ALDH1A1MEN1
SCHEMBL22909451 0.71 TSHR (0.48) TSHR
SCHEMBL29671277 0.70 CA1 (0.35) CA1CA2
SCHEMBL22909293 0.70 CA1 (0.35) CA1CA2
SCHEMBL22909163 0.69 TSHR (0.49) KDM4EKMT2ATSHRLMNASMN1; SMN2
SCHEMBL29671325 0.69 TSHR (0.49) KDM4EKMT2ATSHRLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559454-B2 Benzenesulfonamide derivatives and uses thereof 2692372 ONTARIO, INC. (CA) 2026-02-24 US disclosed
US-20220281812-A1 BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF 2692372 ONTARIO INC (CA) 2022-09-08 US disclosed
EP-4017843-A1 BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF 2692372 Ontario, Inc. (CA) 2022-06-29 EP disclosed
CN-114502533-A Benzenesulfonamide derivatives and use thereof 2692372安大略公司 2022-05-13 CN disclosed
WO-2021009568-A1 BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF 2692372 ONTARIO, INC. (CA) 2021-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12559454-B2 Benzenesulfonamide derivatives and uses thereof NR2E1, NR2C2, NR3C1 CA1 2665/4885CA2 2232/4885SIRT2 3427/4885
US-20220281812-A1 BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF BCR, ARSA, VHL CA1 4526/4885CA2 4102/4885SIRT2 2102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.